Evidence map›Paper›PMID 33472545›Full record

Trial reportAIDS research and human retroviruses2021

Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Karen L Diepstra, Liz Barr, David Palm, Evelyn Hogg, Katie R Mollan, Laney Henley, Angela M Stover, Jane M Simoni, Jeremy Sugarman, Brandon Brown and 7 more

Abstract readClinical Trial
In one paragraph

Trial report in AIDS research and human retroviruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Karen L DiepstraUNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Liz BarrAIDS Clinical Trials Group (ACTG) Community Scientific Sub-Committee, Baltimore, Maryland, USA.
David PalmInstitute of Global Health and Infectious Diseases (IGHID), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Evelyn HoggSocial & Scientific Systems, a DLH Company, Silver Spring, Maryland, USA.
Katie R MollanCenter for AIDS Research (CFAR), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Laney HenleyUNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Angela M StoverUNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
Jane M SimoniDepartment of Psychology, University of Washington, Seattle, Washington, USA.
Jeremy SugarmanJohns Hopkins Berman Institute for Bioethics, Baltimore, Maryland, USA.
Brandon BrownDepartment of Social Medicine, Population and Public Health, Center for Healthy Communities, University of California, Riverside School of Medicine, Riverside, California, USA.
John A SaucedaDivision of Prevention Sciences, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, San Francisco, California, USA.
Steven DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Lawrence FoxNational Institute of Health (NIH) Division of AIDS (DAIDS), Bethesda, Maryland, USA.
Rajesh T GandhiMassachusetts General Hospital, Boston, Massachusetts, USA.
Davey SmithDivision of Infectious Diseases and Global Health, University of California, San Diego, California, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Karine DubéUNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
Pilot Integration of Participant-Centered Outcomes in HIV Cure Research in the United States: Implications for Ethical ConductR21MH118120 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUBE, KARINE · 2019 to 2020
$566k
NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIMH NIH HHS R21 MH118120
6 · The paper itself

Abstract

The AIDS Clinical Trials Group (ACTG) A5345 study included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antiretroviral treatment during chronic HIV infection. We surveyed participant perceptions and understanding of A5345 using a cross-sectional sociobehavioral questionnaire. Participants completed the baseline questionnaire either before or after initiating the study's IMAP. Questionnaire responses were linked to existing demographic data. Quantitative responses were analyzed overall and stratified by IMAP status. Open-ended responses were analyzed using conventional content analysis. Thirty-two participants completed the baseline sociobehavioral questionnaire. Half (

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsBiomarkersCross-Sectional StudiesHumansViral LoadBiomarkersanalytical treatment interruptionbehavioral sciencesHIV cure-related researchintensively monitored antiretroviral pausepersons living with HIVsocial sciences

Identifiers

PMID33472545
PMCPMC8213012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.